Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SYMPHONY-2
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- NCT04762160 ↗
- Terminated
- Epizyme, Inc.
- Focused
We haven't built an HCP commentary report on SYMPHONY-2 (tazemetostat plus rituximab in relapsed/refractory follicular lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SYMPHONY-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Follicular Lymphoma
- Interventions
- Tazemetostat; Rituximab
- Arms
- Tazmetostat in combination with rituximab · Experimental
- Enrollment
- 5
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Epizyme, Inc. with Swedish Cancer Institute
- Start
- Dec 15, 2020
- Primary completion
- Mar 22, 2022
- Results posted
- Yes
- Registry record
- NCT04762160 · updated Mar 25, 2024